Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy.

Molecular tests predicting the risk of distant recurrence (DR) can be used to assist therapy decision-making in oestrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients after considerations of standard clinical markers. The Oncotype DX Recurrence Score (RS) is a widespread tool used for this purpose. Here, we compared the RS with the StemPrintER Risk Score (SPRS), a novel genomic predictor with a unique biological basis in its ability to measure the expression of cancer stemness genes. We benchmarked the SPRS vs. RS, alone or in combination with clinicopathological variables expressed by the Clinical Treatment Score (CTS), for the prognostication of DR in a retrospective cohort of 776 postmenopausal patients with ER+/HER2-breast cancer enrolled in the translational arm of the randomised Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial. Likelihood ratio (LR) with χ In all patients, the SPRS provided significantly more prognostic information than the RS for ten-year DR prognostication (C-index = 0.688, LR-χ In postmenopausal ER+/HER2- breast cancer patients, SPRS provided more prognostic information than RS for DR when used alone or in combination with the CTS. The SPRS could therefore potentially identify high-risk patients, who might benefit from aggressive treatments, from low-risk patients who might safely avoid adjuvant chemotherapy or prolongation of endocrine therapy.

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Pece and Di Fiore report a patent EP/20.06.16/EPA16175354 and a patent EP/20173612.1, both pending to Tiziana Life Sciences (TLS). They also report a research sponsored grant from TLS from June 2014 to June 2018 related to the development of StemPrintER, outside the submitted work which was completely developed with academic funding. Sestak reports personal fees from Myriad Genetics and Pfizer Oncology, outside the submitted work. Viale reports personal fees from Roche Genentech, Daiichi-Sankyo, AstraZeneca, Agilent, Menarini and Ventana, outside the submitted work. Dowsett reports personal fees from Radius, Myriad, Orion, G1, AbbVie, H3 Biomedicine, Lilly, Zentalis, Agilent and Nanostring, outside the submitted work. All other authors declare no other competing interests.